The Pharmacotherapies for Alcohol and Substance Abuse (PASA) Consortium is funded by the Congressionally Directed Medical Research Programs (CDMRP) as part of its Alcohol and Substance Abuse Research Program (ASARP). The goal of the PASA Consortium is to fund study applications for developing new medications that can be brought to therapeutic use to improve treatment outcomes for alcohol and substance use disorders (ASUD), especially as related to post-traumatic stress disorder (PTSD) and traumatic brain injury (TBI).
The two current Research Funding Opportunities are focused on:
1. Request for Application (RFA) #4a: Small-cost and short-duration planning grant awarded to investigators concerning a specific compound or combination of compounds. Designed to determine the clinical development plan (CDP) and associated studies needed to advance the compound to FDA approval for ASUD treatment. The protocol for the first study will be developed as part of the planning grant and will be considered for funding and implementation by the PASA Consortium.
2. Request for Application (RFA) #4b: Full study implementation awards for proof-of-principle basic research to determine which compounds are most appropriate for human research trials
The PASA Consortium is administered by a Management Core led by RTI International in collaboration with the Baylor College of Medicine.
For more information on this opportunity, including application process and timelines, please use the link below: